Background Sunitinib is a tyrosine kinase inhibitor with proven efficacy in renal-cell
carcinoma, but some patients do not respond or need dose reductions due to toxicity …

The multitargeted tyrosine‐kinase inhibitor sunitinib has emerged as one of the standards of
care for good‐and intermediate‐risk metastatic renal cell carcinoma. Although generally …

Purpose: The objective of this study was to identify genetic polymorphisms related to the
pharmacokinetics and pharmacodynamics of sunitinib that are associated with a prolonged …

Sunitinib is a broad-spectrum small-molecule inhibitor of receptor tyrosine kinases (RTK)
that serves as the present standard of care for first-line therapy of advanced clear cell renal …

Resistance to chemotherapeutic agents constitutes a major problem in the treatment of
cancer. Over the past years, multi‐targeted protein kinase inhibitors such as Gleevec …

Background Sunitinib has been approved for the treatment of metastatic renal cell
carcinoma (RCC). Sunitinib pharmacokinetics shows a large interpatient variability. Patients …

Purpose Sunitinib is a first-line advanced renal cell carcinoma (RCC) standard of care. In a
randomized phase II trial comparing sunitinib treatment schedules, separate exploratory …

Background In our exploratory studies, we associated single nucleotide polymorphisms
(SNPs) in candidate genes with the efficacy and toxicities of sunitinib in metastatic renal cell …

Sunitinib has been registered for the treatment of advanced renal cell cancer (RCC). As
patient inclusion was highly selective in previous studies, experience with sunitinib in …

Background: There are no validated markers that predict response in metastatic renal cell
cancer (RCC) patients treated with sunitinib. We aim to study the impact of single-nucleotide …